Related references
Note: Only part of the references are listed.Discovery of multi-target mur enzymes inhibitors with anti-mycobacterial activity through a Scaffold approach
Madhulata Kumari et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions
Ben Gold et al.
ACS INFECTIOUS DISEASES (2022)
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis The COMRADE Randomized, Phase 2A Clinical Trial
Veronique De Jager et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones
Gregory S. Basarab et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment
Eric L. Nuermberger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis
Xi Chen et al.
CURRENT MICROBIOLOGY (2022)
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis
Marion Flipo et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis
Qinglong Guo et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi
Susanne H. Kirsch et al.
NATURAL PRODUCT REPORTS (2022)
Emergence of SpecificgyrA Mutations Associated High-Level Fluoroquinolone-ResistantMycobacterium tuberculosisamong Multidrug-Resistant Tuberculosis Cases in North India
Pravin Kumar Singh et al.
MICROBIAL DRUG RESISTANCE (2021)
rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis
Ma-chao Li et al.
INFECTION AND DRUG RESISTANCE (2021)
Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets
Sangmi Oh et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis
Sarentha Chetty et al.
PHARMACEUTICALS (2021)
The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis
Deepika Rai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis
Amel Kevin Alame Emane et al.
TUBERCULOSIS (2021)
First triclosan-based macrocyclic inhibitors of InhA enzyme
Frederic Rodriguez et al.
BIOORGANIC CHEMISTRY (2020)
In vitro drug discovery models for Mycobacterium tuberculosis relevant for host infection
Tanya Parish
EXPERT OPINION ON DRUG DISCOVERY (2020)
Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from Mycobacterium tuberculosis
Ankita Punetha et al.
ACS CHEMICAL BIOLOGY (2020)
Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs
Liliana Rodrigues et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria
Suzanne S. Stokes et al.
ACS INFECTIOUS DISEASES (2020)
InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis
Lindsay Flint et al.
PLOS ONE (2020)
Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives
Tom Armstrong et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model
Gregory T. Robertson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates
Maha R. Farhat et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
The relevance of persisters in tuberculosis drug discovery
Soma Mandal et al.
MICROBIOLOGY-SGM (2019)
Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes
Eachan O. Johnson et al.
NATURE (2019)
Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV
Elizabeth G. Gibson et al.
BIOCHEMISTRY (2019)
Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase
Antonio Carta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents
Behnoush Hajian et al.
CELL CHEMICAL BIOLOGY (2019)
Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco
Imane Chaoui et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2018)
Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis
Myo T. Zaw et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2018)
The present state of the tuberculosis drug development pipeline
M. Daben J. Libardo et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis
Ningyu Zhu et al.
SCIENTIFIC REPORTS (2018)
Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA
Yi Xia et al.
LIFE SCIENCE ALLIANCE (2018)
Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition
Wei Lin et al.
MOLECULAR CELL (2017)
The challenge of the new tuberculosis drugs
Simon Tiberi et al.
PRESSE MEDICALE (2017)
Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis
Diana Machado et al.
FRONTIERS IN MICROBIOLOGY (2017)
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Omamah Alfarisi et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis
Matthew B. McNeil et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antituberculosis drugs: reducing efflux = increasing activity
Liliana Rodrigues et al.
DRUG DISCOVERY TODAY (2017)
DNA topoisomerase I and DNA gyrase as targets for TB therapy
Valakunja Nagaraja et al.
DRUG DISCOVERY TODAY (2017)
Potent Inhibitors of Acetyltransferase Eis Overcome Kanamycin Resistance in Mycobacterium tuberculosis
Melisa J. Willby et al.
ACS CHEMICAL BIOLOGY (2016)
Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor
Maria Martinez-Hoyos et al.
EBIOMEDICINE (2016)
Repurposing clinically approved cephalosporins for tuberculosis therapy
Santiago Ramon-Garcia et al.
SCIENTIFIC REPORTS (2016)
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain
Shalini Saxena et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening
Ujjini H. Manjunatha et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase
Ningyu Zhu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan
Shu-Ting Tseng et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2015)
Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin
Pooja Singh et al.
JOURNAL OF ANTIBIOTICS (2015)
Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis
Roman Sink et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium tuberculosis Isolates: A Systematic Review
Elisea Avalos et al.
PLOS ONE (2015)
Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review
Marva Seifert et al.
PLOS ONE (2015)
Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis
Wei Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study
Gerald Mboowa et al.
BMC INFECTIOUS DISEASES (2014)
Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases
Kai Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Koen Andries et al.
PLOS ONE (2014)
Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance
Babak Javid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities
Catherine Vilcheze et al.
MICROBIOLOGY SPECTRUM (2014)
Aminopyrazinamides: Novel and Specific GyrB Inhibitors that Kill Replicating and Nonreplicating Mycobacterium tuberculosis
Pravin S. Shirude et al.
ACS CHEMICAL BIOLOGY (2013)
Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds
Pan Pan et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
Towards a new tuberculosis drug: pyridomycin - nature's isoniazid
Ruben C. Hartkoorn et al.
EMBO MOLECULAR MEDICINE (2012)
Reappraising the use of β-lactams to treat tuberculosis
Sebastian G. Kurz et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Myungsun Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs
Jotam G. Pasipanodya et al.
CURRENT OPINION IN PHARMACOLOGY (2011)
First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital
A. Soudani et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance
G. E. Louw et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Synthetic EthR inhibitors boost antituberculous activity of ethionamide
Nicolas Willand et al.
NATURE MEDICINE (2009)
Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
Jean-Emmanuel Hugonnet et al.
SCIENCE (2009)
Mycobacterium tuberculosis DNA gyrase:: Interaction with quinolones and correlation with antimycobacterial drug activity
A Aubry et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations
C Cavusoglu et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase:: Adduct affinity and drug resistance
R Rawat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase
TA Vannelli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
